4.15
0.04 (0.97%)
| Previous Close | 4.11 |
| Volume | 23,543 |
| Price / Sales | 2.55 |
| Price / Book | 18.63 |
| 52 Weeks Range |
| Operating Margin (TTM) | -236.41% |
| Diluted EPS (TTM) | -11.40 |
| Quarterly Revenue Growth (YOY) | -10.10% |
| Current Ratio (MRQ) | 1.34 |
| Operating Cash Flow (TTM) | -53.66 M |
| Levered Free Cash Flow (TTM) | -32.56 M |
| Return on Assets (TTM) | -62.87% |
| Return on Equity (TTM) | -1,546.58% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Verrica Pharmaceuticals Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | -3.5 |
| Technical Oscillators | -2.5 |
| Relative Valuation | NA |
| Financial Health | -2.5 |
| AI Insight | NA |
| Average | -1.93 |
Select this tab to load the latest available analysis.
|
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 44.90% |
| % Held by Institutions | 32.25% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |